Sonnet BioTherapeutics Holdings Inc. (NASDAQ: SONN)
$0.88
-0.0100 ( -1.12% ) 64.5K
Sonnet BioTherapeutics Holdings Inc is a clinical-stage biotechnology company. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others.
Market Data
Open
$0.88
Previous close
$0.89
Volume
64.5K
Market cap
$4.70M
Day range
$0.86 - $0.90
52 week range
$0.83 - $10.09
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
pre | Proxies and info statements | 3 | Jul 28, 2023 |
8-k | 8K-related | 12 | Jul 21, 2023 |